(firstQuint)Phase 1 Study(Additional) of URC102 in Healthy Subjects.

 Tolerability, safety, and pharmacokinetics (PK) of URC102 will be assessed after 7-day repeated oral dose in healthy adult Korean males.

 In addition, pharmacodynamic (PD) response of blood and urinary uric acid levels will be assessed.

.

 Phase 1 Study(Additional) of URC102 in Healthy Subjects@highlight

The purpose of this study is to assess the safety, tolerability, PK and PD of URC102 in healthy subjects.

